Tweet
[Source: US National Library of Medicine, (LINK). Edited.]
Antimicrob Agents Chemother. 2010 Apr 19. [Epub ahead of print]
Prophylactic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H274Y Neuraminidase Mutation.
Abed Y, Simon P, Boivin G. - Research Center in Infectious Diseases of the CHUQ-CHUL and Laval University, Qu?bec City, Qu?bec, Canada.
Peramivir is a neuraminidase (NA) inhibitor under development that must be administered by the systemic route. The prophylactic activity of intramuscular (IM) peramivir was evaluated in mice infected with wild-type (WT) and oseltamivir-resistant (H274Y NA mutant) recombinant influenza A/WSN/33 (H1N1) viruses. Treatment regimens consisted on single (45 mg/kg or 90 mg/kg) or multiple (45 mg/kg daily for 5 days) IM injections that started 1 h before viral challenge. All peramivir regimens prevented mortality and weight loss while significantly reducing lung viral titers (LVT) in mice infected with the WT virus. For the H274Y mutant, the multiple doses regimen completely prevented mortality and was associated with significant reduction in weight loss and LVT compared to untreated animals. In contrast, both single treatment regimens reduced mortality and weight loss but did not significantly reduce LVT. Although further experiments using different influenza A/H1N1 strains and other animal models are needed, our results suggest that five-day IM peramivir therapy may be considered as a prophylactic alternative to control influenza infections caused by oseltamivir-resistant viruses with the H274Y mutation.
PMID: 20404128 [PubMed - as supplied by publisher]
-
------
Antimicrob Agents Chemother. 2010 Apr 19. [Epub ahead of print]
Prophylactic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H274Y Neuraminidase Mutation.
Abed Y, Simon P, Boivin G. - Research Center in Infectious Diseases of the CHUQ-CHUL and Laval University, Qu?bec City, Qu?bec, Canada.
Peramivir is a neuraminidase (NA) inhibitor under development that must be administered by the systemic route. The prophylactic activity of intramuscular (IM) peramivir was evaluated in mice infected with wild-type (WT) and oseltamivir-resistant (H274Y NA mutant) recombinant influenza A/WSN/33 (H1N1) viruses. Treatment regimens consisted on single (45 mg/kg or 90 mg/kg) or multiple (45 mg/kg daily for 5 days) IM injections that started 1 h before viral challenge. All peramivir regimens prevented mortality and weight loss while significantly reducing lung viral titers (LVT) in mice infected with the WT virus. For the H274Y mutant, the multiple doses regimen completely prevented mortality and was associated with significant reduction in weight loss and LVT compared to untreated animals. In contrast, both single treatment regimens reduced mortality and weight loss but did not significantly reduce LVT. Although further experiments using different influenza A/H1N1 strains and other animal models are needed, our results suggest that five-day IM peramivir therapy may be considered as a prophylactic alternative to control influenza infections caused by oseltamivir-resistant viruses with the H274Y mutation.
PMID: 20404128 [PubMed - as supplied by publisher]
-
------